Diabetic Retinopathy: From Pathogenesis to TreatmentView this Special Issue
Research Article | Open Access
Inhibition of Advanced Glycation and Absence of Galectin-3 Prevent Blood-Retinal Barrier Dysfunction during Short-Term Diabetes
Breakdown of the inner blood-retinal barrier (iBRB) occurs early in diabetes and is central to the development of sight-threatening diabetic macular edema (DME) as retinopathy progresses. In the current study, we examined how advanced glycation end products (AGEs) forming early in diabetes could modulate vasopermeability factor expression in the diabetic retina and alter inter-endothelial cell tight junction (TJ) integrity leading to iBRB dysfunction. We also investigated the potential for an AGE inhibitor to prevent this acute pathology and examined a role of the AGE-binding protein galectin-3 (Gal-3) in AGE-mediated cell retinal pathophysiology. Diabetes was induced in C57/BL6 wild-type (WT) mice and in Gal- transgenic mice. Blood glucose was monitored and AGE levels were quantified by ELISA and immunohistochemistry. The diabetic groups were subdivided, and one group was treated with the AGE-inhibitor pyridoxamine (PM) while separate groups of WT and Gal- mice were maintained as nondiabetic controls. iBRB integrity was assessed by Evans blue assay alongside visualisation of TJ protein complexes via occludin-1 immunolocalization in retinal flat mounts. Retinal expression levels of the vasopermeability factor VEGF were quantified using real-time RT-PCR and ELISA. WT diabetic mice showed significant AGE -immunoreactivity in the retinal microvasculature and also showed significant iBRB breakdown (). These diabetics had higher VEGF mRNA and protein expression in comparison to controls (). PM-treated diabetics had normal iBRB function and significantly reduced diabetes-mediated VEGF expression. Diabetic retinal vessels showed disrupted TJ integrity when compared to controls, while PM-treated diabetics demonstrated near-normal configuration. Gal- mice showed significantly less diabetes-mediated iBRB dysfunction, junctional disruption, and VEGF expression changes than their WT counterparts. The data suggests an AGE-mediated disruption of iBRB via upregulation of VEGF in the diabetic retina, possibly modulating disruption of TJ integrity, even after acute diabetes. Prevention of AGE formation or genetic deletion of Gal-3 can effectively prevent these acute diabetic retinopathy changes.
- R. J. Antcliff and J. Marshall, “The pathogenesis of edema in diabetic maculopathy,” Seminars in Ophthalmology, vol. 14, no. 4, pp. 223–232, 1999.
- C. Engler, B. Krogsaa, and H. Lund-Andersen, “Blood-retina barrier permeability and its relation to the progression of diabetic retinopathy in type 1 diabetes. An 8-year follow-up study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 229, no. 5, pp. 442–446, 1991.
- B. Sander, M. Larsen, C. Engler et al., “Diabetic macular oedema: a comparison of vitreous fluorometry, angiography, and retinopathy,” British Journal of Ophthalmology, vol. 86, no. 3, pp. 316–320, 2002.
- G. L. Trick, J. Liggett, J. Levy et al., “Dynamic contrast enhanced MRI in patients with diabetic macular edema: initial results,” Experimental Eye Research, vol. 81, no. 1, pp. 97–102, 2005.
- M. S. Roy, M. J. Podgor, P. Bungay, G. Grunberger, J. Carl, and D. Ellis, “Posterior vitreous fluorophotometry in diabetic patients with minimal or no retinopathy,” Retina, vol. 7, no. 3, pp. 170–176, 1987.
- J. Cunha-Vaz, C. Lobo, J. C. Sousa, B. Oliveiros, E. Leite, and J. R. Faria de Abreu, “Progression of retinopathy and alteration of the blood-retinal barrier in patients with type 2 diabetes: a 7-year prospective follow-up study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 236, no. 4, pp. 264–268, 1998.
- A. B. El-Remessy, M. A. Behzadian, G. Abou-Mohamed, T. Franklin, R. W. Caldwell, and R. B. Caldwell, “Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor,” American Journal of Pathology, vol. 162, no. 6, pp. 1995–2004, 2003.
- T. Qaum, Q. Xu, A. M. Joussen et al., “VEGF-initiated blood-retinal barrier breakdown in early diabetes,” Investigative Ophthalmology and Visual Science, vol. 42, no. 10, pp. 2408–2413, 2001.
- R. H. Amin, R. N. Frank, A. Kennedy, D. Eliott, J. E. Puklin, and G. W. Abrams, “Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy,” Investigative Ophthalmology and Visual Science, vol. 38, no. 1, pp. 36–47, 1997.
- D. A. Antonetti, A. J. Barber, L. A. Hollinger, E. B. Wolpert, and T. W. Gardner, “Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors,” Journal of Biological Chemistry, vol. 274, no. 33, pp. 23463–23467, 1999.
- A. J. Barber and D. A. Antonetti, “Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats,” Investigative Ophthalmology and Visual Science, vol. 44, no. 12, pp. 5410–5416, 2003.
- S. Ishida, T. Usui, K. Yamashiro et al., “VEGF164 is proinflammatory in the diabetic retina,” Investigative Ophthalmology and Visual Science, vol. 44, no. 5, pp. 2155–2162, 2003.
- L. P. Aiello, S.-E. Bursell, A. Clermont et al., “Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective -isoform-selective inhibitor,” Diabetes, vol. 46, no. 9, pp. 1473–1480, 1997.
- R. Rota, C. Chiavaroli, R. P. Garay, and P. Hannaert, “Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats,” European Journal of Pharmacology, vol. 495, no. 2-3, pp. 217–224, 2004.
- A. K. H. Cheung, M. K. L. Fung, A. C. Y. Lo et al., “Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice,” Diabetes, vol. 54, no. 11, pp. 3119–3125, 2005.
- I. G. Obrosova, A. G. Minchenko, R. Vasupuram et al., “Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats,” Diabetes, vol. 52, no. 3, pp. 864–871, 2003.
- S. R. Thorpe and J. W. Baynes, “Maillard reaction products in tissue proteins: new products and new perspectives,” Amino Acids, vol. 25, no. 3-4, pp. 275–281, 2003.
- H.-P. Hammes, A. Alt, T. Niwa et al., “Differential accumulation of advanced glycation end products in the course of diabetic retinopathy,” Diabetologia, vol. 42, no. 6, pp. 728–736, 1999.
- N. Karachalias, R. Babaei-Jadidi, N. Ahmed, and P. J. Thornalley, “Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats,” Biochemical Society Transactions, vol. 31, part 6, pp. 1423–1425, 2003.
- A. W. Stitt, Y. M. Li, T. A. Gardiner, R. Bucala, D. B. Archer, and H. Vlassara, “Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats,” American Journal of Pathology, vol. 150, no. 2, pp. 523–531, 1997.
- A. W. Stitt, T. Bhaduri, C. B. T. McMullen, T. A. Gardiner, and D. B. Archer, “Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats,” Molecular Cell Biology Research Communications, vol. 3, no. 6, pp. 380–388, 2000.
- A. W. Stitt, T. A. Gardiner, N. L. Anderson et al., “The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes,” Diabetes, vol. 51, no. 9, pp. 2826–2832, 2002.
- T. A. Gardiner, H. R. Anderson, and A. W. Stitt, “Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes,” Journal of Pathology, vol. 201, no. 2, pp. 328–333, 2003.
- A. Bierhaus, M. A. Hofmann, R. Ziegler, and P. P. Nawroth, “AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept,” Cardiovascular Research, vol. 37, no. 3, pp. 586–600, 1998.
- A. M. Schmidt, S. D. Yan, S. F. Yan, and D. M. Stern, “The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses,” Journal of Clinical Investigation, vol. 108, no. 7, pp. 949–955, 2001.
- A. W. Stitt, C. McGoldrick, A. Rice-McCaldin et al., “Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3,” Diabetes, vol. 54, no. 3, pp. 785–794, 2005.
- M. Lu, M. Kuroki, S. Amano et al., “Advanced glycation end products increase retinal vascular endothelial growth factor expression,” Journal of Clinical Investigation, vol. 101, no. 6, pp. 1219–1224, 1998.
- S.-I. Yamagishi, H. Yonekura, Y. Yamamoto et al., “Advanced glycation end products-driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor,” Journal of Biological Chemistry, vol. 272, no. 13, pp. 8723–8730, 1997.
- S. McFarlane, J. V. Glenn, A. M. Lichanska, D. A. C. Simpson, and A. W. Stitt, “Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium,” British Journal of Ophthalmology, vol. 89, no. 1, pp. 107–112, 2005.
- K. Otero, F. Martínez, A. Beltrán et al., “Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells,” Biochemical Journal, vol. 359, part 3, pp. 567–574, 2001.
- G. Leto, F. Pricci, L. Amadio et al., “Increased retinal endothelial cell monolayer permeability induced by the diabetic milieu: role of advanced non-enzymatic glycation and polyol pathway activation,” Diabetes/Metabolism Research and Reviews, vol. 17, no. 6, pp. 448–458, 2001.
- T. C. B. Moore, J. E. Moore, Y. Kaji et al., “The role of advanced glycation end products in retinal microvascular leukostasis,” Investigative Ophthalmology and Visual Science, vol. 44, no. 10, pp. 4457–4464, 2003.
- D. K. Hsu, R.-Y. Yang, Z. Pan et al., “Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses,” American Journal of Pathology, vol. 156, no. 3, pp. 1073–1083, 2000.
- O. T. Cox, D. A. C. Simpson, A. W. Stitt, and T. A. Gardiner, “Sources of PDGF expression in murine retina and the effect of short-term diabetes,” Molecular Vision, vol. 10, no. 9, pp. 665–672, 2003.
- B. Brankin, M. Campbell, P. Canning, T. A. Gardiner, and A. W. Stitt, “Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium,” Experimental Eye Research, vol. 81, no. 1, pp. 22–31, 2005.
- D. A. Simpson, S. Feeney, C. Boyle, and A. W. Stitt, “Retinal VEGF mRNA measured by SYBR green I fluorescence: a versatile approach to quantitative PCR,” Molecular Vision, vol. 6, pp. 178–183, 2000.
- A. M. Joussen, V. Poulaki, N. Mitsiades et al., “Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF- suppression,” The FASEB Journal, vol. 16, no. 3, pp. 438–440, 2002.
- A. M. Joussen, V. Poulaki, W. Qin et al., “Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo,” American Journal of Pathology, vol. 160, no. 2, pp. 501–509, 2002.
- A. W. Stitt and T. M. Curtis, “Advanced glycation and retinal pathology during diabetes,” Pharmacological Reports, vol. 57, supplement, pp. 156–168, 2005.
- P. S. Padayatti, C. Jiang, M. A. Glomb, K. Uchida, and R. H. Nagaraj, “High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells,” Current Eye Research, vol. 23, no. 2, pp. 106–115, 2001.
- D. Yao, T. Taguchi, T. Matsumura et al., “Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription,” Cell, vol. 124, no. 2, pp. 275–286, 2006.
- I. Giardino, D. Edelstein, and M. Brownlee, “Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes,” Journal of Clinical Investigation, vol. 94, no. 1, pp. 110–117, 1994.
- A. W. Stitt, U. Chakravarthy, D. B. Archer, and T. A. Gardiner, “Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of nonenzymatic glycosylation,” Diabetologia, vol. 38, no. 11, pp. 1271–1275, 1995.
- D. S. Fosmark, P. A. Torjesen, B. K. Kilhovd et al., “Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus,” Metabolism, vol. 55, no. 2, pp. 232–236, 2006.
- D. J. McKenna, J. Nelson, and A. W. Stitt, “Advanced glycation alters expression of the 67kDa laminin receptor in retinal microvascular endothelial cells,” Life Sciences, vol. 68, no. 24, pp. 2695–2703, 2001.
- H.-P. Hammes, D. Strodter, A. Weiss, R. G. Bretzel, K. Federlin, and M. Brownlee, “Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model,” Diabetologia, vol. 38, no. 6, pp. 656–660, 1995.
- N. L. Alderson, M. E. Chachich, N. N. Youssef et al., “The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats,” Kidney International, vol. 63, no. 6, pp. 2123–2133, 2003.
- R. H. Nagaraj, P. Sarkar, A. Mally, K. M. Biemel, M. O. Lederer, and P. S. Padayatti, “Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal,” Archives of Biochemistry and Biophysics, vol. 402, no. 1, pp. 110–119, 2002.
- C. Treins, S. Giorgetti-Peraldi, J. Murdaca, and E. Van Obberghen, “Regulation of vascular endothelial growth factor expression by advanced glycation end products,” Journal of Biological Chemistry, vol. 276, no. 47, pp. 43836–43841, 2001.
- J. Dumic, S. Dabelic, and M. Flögel, “Galectin-3: an open-ended story,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1760, no. 4, pp. 616–635, 2006.
- H. Vlassara, R. Bucala, and L. Striker, “Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging,” Laboratory Investigation, vol. 70, no. 2, pp. 138–151, 1994.
- W. Zhu, H. Sano, R. Nagai, K. Fukuhara, A. Miyazaki, and S. Horiuchi, “The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins,” Biochemical and Biophysical Research Communications, vol. 280, no. 4, pp. 1183–1188, 2001.
- G. Pugliese, F. Pricci, G. Leto et al., “The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression,” Diabetes, vol. 49, no. 7, pp. 1249–1257, 2000.
- G. Pugliese, F. Pricci, C. Iacobini et al., “Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice,” The FASEB Journal, vol. 15, no. 13, pp. 2471–2479, 2001.
- F.-T. Liu, R. J. Patterson, and J. L. Wang, “Intracellular functions of galectins,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1572, no. 2-3, pp. 263–273, 2002.
- C. Colnot, M.-A. Ripoche, G. Milon, X. Montagutelli, P. R. Crocker, and F. Poirier, “Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice,” Immunology, vol. 94, no. 3, pp. 290–296, 1998.
- H. Sano, D. K. Hsu, J. R. Apgar et al., “Critical role of galectin-3 in phagocytosis by macrophages,” Journal of Clinical Investigation, vol. 112, no. 3, pp. 389–397, 2003.
Copyright © 2007 Paul Canning et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.